Join us on May 3-5 for SAA's first Global Spondyloarthritis Summit featuring some of the most respected medical professionals, including renowned rheumatologists, a physical therapist, pain management specialist, and others to discuss the latest treatment options and research in spondyloarthritis.
To be a leader in the quest to cure ankylosing spondylitis and related diseases, and to empower those affected to live their lives to the fullest.
Think your pain may be caused by spondylitis? Watch our new awareness video and take the quiz!
Connect with others because no one should have to face spondylitis alone.
The most comprehensive library of spondylitis information and educational materials.
Spondylitis is a relatively unknown disease, but it affects 1 in 100 Americans.
There are many ways to get involved in the community. Which one’s right for you?
Use our state-by-state list of patient recommended and board certified rheumatologists.
View the Directory
Posted March 2019
On March 28, 2019, the U.S. FDA announced the approval of the TNF inhibitor, certolizumab pegol (CIMZIA®) for the treatment for non-radiographic axial spondyloarthritis (nr-axSpA.) This is the first, and currently only biologic agent to gain approval for nr-axSpA in the U.S., providing those living with the condition access to a new class of medication.
Posted March 2018
If you’ve been using a drug manufacturer’s copay discount card to help with your out-of-pocket costs for a biologic or other specialty medication, you may soon be in for a surprise. Several large insurance companies and pharmacy benefit managers (PBMs) are implementing new schemes called “copay accumulator programs” that affect how contributions from those same copay cards are applied to your annual out-of-pocket cost requirements.
We offer a wide variety of resources for members of the spondylitis community, physicians and others who are interested in learning more about spondylitis.